Smooth Sailing Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD
- Listen to this Article
- Trial Design
- Efficacy
- Safety
This morning, Definium Therapeutics announced positive topline results from its Phase 3 study of LSD (DT120) for generalised anxiety disorder (GAD).
It comes just two months after it posted positive topline results from its first Phase 3 program in major depressive disorder (MDD), Emerge, making it a successful summer for the LSD developer...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks
Already a member?
Sign In